Filed under: Bureaucracy, Domestic Policy, Economics, Economy, Education, Free Markets, Freedom, Health Care, Politics, Progressives, Regulation, Science/Technology | Tags: Congressional Hearings, Food and Drug Administration, Scott Gottlieb M.D.
With the exposure of the Susan Rice story, and the dreadful sarin gas attack in Syria by the Assad administration on his own people other things escape our attention. The confirmation hearings for Dr. Scott Gottlieb who the president has nominated to run the Food and Drug Administration (FDA) didn’t get a lot of notice.
Our very own Seattle Senator Patty Murray and other Democrats devoted the morning to attacking Dr. Gottlieb for his “unprecedented financial entanglements” because he has consulted for various companies and invested in health-care start-ups. (Possibly because that is his area of expertise?) Sheldon Whitehouse suggested “dark money operations,” which is a strange description of financial disclosures available to all on the internet. Bernie Sanders tweeted that it was a “disgrace” to have an FDA commissioner who has taken money from drug companies.
These are the same committee Democrats who attacked Betsy DeVos for not having enough experience in public education, nor experience in government. Consistency and hypocrisy are ongoing problems for the Democrats.
Dr. Gottlieb not only disclosed all his work in accordance with government rules and will liquidate his investments, he agreed to recuse himself for a year on decisions involving his past interests. He also promised to follow directions from the HHS ethics office and to be an “impartial and independent advocate for the public health.”
Another remarkable ugly charge was that Dr. Gottlieb would not address the opioid crisis because he has worked with companies that produce painkillers. Desperate Democrats, out of power, are having trouble finding believable or even sane talking points.
Dr. Gottlieb has called the opioid crisis “a public emergency on the order of Ebola and Zika” and suggested an “all-of-the-above” strategy that would include creating new painkillers that were less addictive and better patient care. He hopes to increase generic drug competition. He offered a tutorial in how companies exploit the regulatory barriers to competition for their commercial advantage,
He has written about how the FDA can unleash innovation without compromising public safety. Democrats, always confused about the evils of “profit” have forgotten about the immense value of expertise. This is another of President Trump’s outstanding nominees, so of course he should be attacked. It will be good to have someone who understands the needs of patients and their doctors and the pharmaceutical industry in that office.
1 Comment so far
Leave a comment